Table 2 Named patient programmes in the Netherlands, Turkey and the United States.
The Netherlands | Turkey | United States | |
|---|---|---|---|
Applicability | Post phase IIa | Mostly drugs that are approved in other countries | Post phase II |
Financing | Pharmaceutical companies | Social Security Institution | Pharmaceutical companies, patients |
Uptake | 100–200 per yearVI | 25,000 per yearVII | 1000 per yearVIII |
Oversight | Health and Youth Inspectorate (IGJ) | Ministry of Health | Food and Drug Administration (FDA) |
Evaluation by Ethics Review Committee | Not applicable | Not applicable | Necessary |
